Why the study?
Sustained β-adrenergic activation induces cardiac fibrosis, and EP4 is essential for cardiovascular homeostasis, but the roles of cardiomyocyte and cardiac fibroblast EP4 in ISO-induced cardiac fibrosis remain to be investigated.
Does targeting the E Prostanoid Receptor EP4 mitigate cardiac fibrosis induced by β-adrenergic activation in mice?
Does targeting the E Prostanoid Receptor EP4 mitigate cardiac fibrosis induced by β-adrenergic activation in mice?
Targeting the EP4 receptor in cardiomyocytes and cardiac fibroblasts mitigates β-adrenergic activation-induced cardiac fibrosis, suggesting a novel therapeutic approach.
No takes yet. Share an insight, caveat, or question.
EP4 blockade improves diastolic function in this mouse model; leaves open translation to human HF therapy.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: